Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00297414 · ClinicalTrials.gov registry record

An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

A clinical trial of Mild Cognitive Impairment, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Completed
Registry status
1,083
Enrollment target
20
Study locations

NCT00297414: Completed study of Mild Cognitive Impairment, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

NCT00297414 is a study of Mild Cognitive Impairment that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 1,083 participants, below the 1,265-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00297414, a study of Mild Cognitive Impairment, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

COMPLETED
Registry status
1,083 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to collect data of patients who were randomized (assignment of study medication by chance) and treated in 3 previous studies of galantamine (CR003145, CR002014 and CR005947) for the treatment of mild cognitive impairment (isolated memory impairment). This data were not recorded during the course of these 3 previous studies.

Primary Outcome

Poststudy vital status (living or deceased) of patients who participated in 3 clinical studies with galantamine will be evaluated. Data will be collected as vital status of the patient, date of death, cause of death and adverse events associated with death.

Conditions Studied

Mild Cognitive Impairment

Interventions

  • OTHER No intervention

Study Locations (20)

California

  • - Laguna Woods
  • - Northridge
  • - Oceanside
  • - Paramount
  • - San Diego
  • - San Francisco

Florida

  • - Fort Lauderdale
  • - Miami
  • - North Miami
  • - Oscala F
  • - St. Petersburg
  • - West Palm Beach

Connecticut

  • - Hamden
  • - Hartford
  • - New Haven

Arizona

  • - Tucson

Georgia

  • - Atlanta

Illinois

  • - Chicago

Kentucky

  • - Paducah

Maryland

  • - Glen Burnie

Trial Details

FieldValue
Enrollment Target 1,083 participants
Start Date 2004-06
Est. Completion 2005-01
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

102 total trials

What the finished NCT00297414 record still lists

NCT00297414 is an observational study that tracks outcomes without assigning an intervention. Its 1,083 participants enrollment target places it among the larger protocols in the corpus, below the 1,265-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (14% lower).

The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.

NCT00297414 names 20 study sites across 8 states, led by California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00297414 about?

NCT00297414 is a clinical study titled "An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine". The purpose of the study is to collect data of patients who were randomized (assignment of study medication by chance) and treated in 3 previous studies of galantamine (CR003145, CR002014 and CR005947) for the treatment of mild cognitive impairment (isolated memory impairment). This data were not re...

What is the current status of trial NCT00297414?

This trial is currently completed. The enrollment target is 1,083 participants. The study started on 2004-06. Estimated completion is 2005-01.

What conditions does trial NCT00297414 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment.

What interventions are being tested in trial NCT00297414?

The interventions under investigation include: No intervention (OTHER).

Who is sponsoring clinical trial NCT00297414?

This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00297414 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00297414's enrollment target sits among peer trials

1,083 13th of 205 higher than 193 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06074068 · 1,080 participants · NA

    Father-Focused Intervention for Reducing Family Violence and Symptoms in Children

  • NCT07213804 · 1,080 participants · Phase 3

    A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

  • NCT06671483 · 1,088 participants · Phase 3

    A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  • NCT07084883 · 1,076 participants

    Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00297414, the US trial registry maintained by the National Library of Medicine. NCT00297414 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.